Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-80 will be recruited.~* All will have an established radiological diagnosis of bronchiectasis (CT of the chest).~* Patients colonised with Pseudomonas Aeruginosa.~* Able to give informed consent.~Exclusion Criteria:~* Current smokers or ex-smokers of less than 1 year; \>15 pack year history~* Cystic fibrosis~* Active allergic bronchopulmonary aspergillosis~* Active tuberculosis~* Poorly controlled asthma~* Pregnancy or breast feeding~* Known allergy to statins~* Active malignancy~* Chronic liver disease~* Established cardiovascular or cerebrovascular disease~* Statin use in the last year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ATORVASTATIN (Type: ACTIVE_COMPARATOR): Atorvastatin 80mg once daily for 3 months, 1.5 month wash out, then Placebo for 3 months
- PLACEBO (Type: PLACEBO_COMPARATOR): Placebo 3 months, then washout for 1.5 months, then Atorvastatin 80mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).